Published in J Ovarian Res on February 06, 2014
PROGgeneV2: enhancements on the existing database. BMC Cancer (2014) 1.07
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget (2015) 1.07
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol (2014) 0.95
Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cells. J Ovarian Res (2015) 0.78
Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. Sci Rep (2016) 0.77
Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy. Med Sci Monit (2017) 0.75
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell (2017) 0.75
Comprehensive discovery of subsample gene expression components by information explanation: therapeutic implications in cancer. BMC Med Genomics (2017) 0.75
Inhibition of ovarian cancer proliferation and invasion by pachymic acid. Int J Clin Exp Pathol (2015) 0.75
VSV based virotherapy in ovarian cancer: the past, the present and …future? J Cancer (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 10.38
The many ways of Wnt in cancer. Curr Opin Genet Dev (2007) 6.29
Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (1988) 6.02
The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod (1989) 4.13
Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem (1996) 3.95
Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium (2005) 3.46
Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer (2005) 3.20
Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol (2009) 2.89
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43
Activation of the protein kinase Akt/PKB by the formation of E-cadherin-mediated cell-cell junctions. Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex. J Biol Chem (1999) 2.06
Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res (1998) 2.01
Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell (2003) 1.81
Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res (2001) 1.77
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 1.75
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology (2006) 1.73
Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol (2009) 1.69
Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun (2010) 1.67
Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther (2008) 1.61
beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol (1999) 1.55
E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer (1997) 1.51
Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol (2003) 1.45
Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer (2007) 1.35
beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer (1999) 1.31
Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res (2002) 1.29
Expression of E-cadherin and N-cadherin in surface epithelial-stromal tumors of the ovary distinguishes mucinous from serous and endometrioid tumors. Hum Pathol (1997) 1.28
β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One (2011) 1.25
Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol Endocrinol (2005) 1.25
Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol (2004) 1.23
Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology (1998) 1.22
WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Mol Cancer Res (2012) 1.21
Planar cell polarity signaling: a common mechanism for cellular polarization. Mt Sinai J Med (2006) 1.18
E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene (2009) 1.18
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer (2008) 1.15
Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer (1999) 1.14
Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep (2009) 1.13
Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol (1995) 1.12
Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene (2006) 1.10
Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Gynecol Oncol (2008) 1.05
Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer (2011) 1.05
Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol (2006) 1.04
The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol (1989) 1.01
Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol (2008) 1.01
Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol (2004) 1.01
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol (2000) 1.00
Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol (2006) 0.98
Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol (1988) 0.95
Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 0.94
The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol (2004) 0.92
Effect of downregulated β-catenin on cell proliferative activity, the sensitivity to chemotherapy drug and tumorigenicity of ovarian cancer cells. Cell Mol Biol (Noisy-le-grand) (2011) 0.87
High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma. Eur J Cancer (2010) 0.85
Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance. Eur J Pharmacol (2006) 0.84
Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol (2009) 0.83
The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet (2010) 0.83
E-Cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol (2000) 0.81
Ovarian cancer management. Practice guidelines for nuclear physicians. Q J Nucl Med Mol Imaging (2004) 0.78
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol (2013) 3.48
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer (2009) 1.72
Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. J Cancer Res Clin Oncol (2007) 1.59
Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells. Cancer Biol Ther (2007) 1.57
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst (2008) 1.53
Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev (2005) 1.41
Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer (2008) 1.37
Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer (2010) 1.35
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol (2012) 1.19
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer (2012) 1.17
The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochim Biophys Acta (2010) 1.16
Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat (2009) 1.14
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol (2007) 1.13
Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. J Exp Clin Cancer Res (2009) 1.07
Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res (2011) 1.04
Image processing for accurate cell recognition and count on histologic slides. Anal Quant Cytol Histol (2006) 1.03
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer (2010) 1.02
Comparative analysis of methods for accurate recognition of cells through nuclei staining of Ki-67 in neuroblastoma and estrogen/progesterone status staining in breast cancer. Anal Quant Cytol Histol (2009) 1.02
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. J Cancer Res Clin Oncol (2014) 0.95
Ovarian cancer as a genetic disease. Front Biosci (Landmark Ed) (2013) 0.93
Computer system for cell counting in selected brain tumors at Ki-67 immunohistochemical staining. Anal Quant Cytol Histol (2010) 0.92
Buffering capacity explains signal variation in symbiotic calcium oscillations. Plant Physiol (2012) 0.92
Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. Kidney Blood Press Res (2010) 0.90
Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system. Onco Targets Ther (2013) 0.89
The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol (2011) 0.89
K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. Cancer Biol Ther (2012) 0.89
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol (2011) 0.88
Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit Rev Oncol Hematol (2011) 0.88
Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol (2007) 0.88
Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial. Oncologist (2014) 0.88
Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev (2009) 0.87
Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res (2011) 0.87
Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer Res (2013) 0.87
A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol (2011) 0.86
Colocalization of BAX with BID and VDAC-1 in nimesulide-induced apoptosis of human colon adenocarcinoma COLO 205 cells. Anticancer Drugs (2002) 0.84
Evaluation of mRNA expression of estrogen receptor beta and its isoforms in human normal and neoplastic endometrium. Int J Cancer (2004) 0.84
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest (2010) 0.84
Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma. Cardiology (2009) 0.83
Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev (2009) 0.83
Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. Future Oncol (2014) 0.82
Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy. Int J Gynecol Cancer (2014) 0.82
Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib. J Oncol Pharm Pract (2012) 0.81
Targeted therapy of renal cell cancer. Curr Opin Investig Drugs (2008) 0.81
Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option? Arch Med Sci (2012) 0.81
Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review). Oncol Lett (2010) 0.80
A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int (2010) 0.79
Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity. Oncogene (2005) 0.79
Future perspectives for mTOR inhibitors in renal cell cancer treatment. Future Oncol (2015) 0.79
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs (2013) 0.79
Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience. Jpn J Clin Oncol (2006) 0.78
Skull base secretory meningioma. Value of histological and immunohistochemical findings for peritumoral brain edema formation. Neuro Endocrinol Lett (2013) 0.78
Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. J Cancer Res Clin Oncol (2008) 0.78
[Difficulties in echocardiographic monitoring of trastuzumab therapy in breast cancer patients: case report and review of recommendations]. Kardiol Pol (2008) 0.78
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. J Cancer Res Clin Oncol (2009) 0.78
Colorectal cancer in the course of familial adenomatous polyposis syndrome ("de novo" pathogenic mutation of APC gene): case report, review of the literature and genetic commentary. Arch Med Sci (2010) 0.78
Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. Kidney Blood Press Res (2012) 0.77
The influence of the microscope lamp filament colour temperature on the process of digital images of histological slides acquisition standardization. Diagn Pathol (2014) 0.77
Manageability of acute severe heart failure complicated with left ventricular thrombosis during therapy for breast cancer. Int Heart J (2010) 0.77
Increased cyclooxygenase expression and thymine dimer formation after repeated exposures of humans to low doses of solar simulated radiation. Exp Dermatol (2007) 0.77
[Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation]. Ginekol Pol (2012) 0.77
Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. Future Oncol (2015) 0.77
[CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction]. Ginekol Pol (2008) 0.76
[Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers]. Ginekol Pol (2014) 0.76
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol (2009) 0.76
The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy. Future Oncol (2014) 0.76
Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region. Expert Opin Pharmacother (2011) 0.75
Malignant tumors in patients with end stage renal failure undergoing renal replacement therapy. Contemp Oncol (Pozn) (2012) 0.75
Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - apoptosis-regulating factors. Contemp Oncol (Pozn) (2012) 0.75
The role of the cell-cell interactions in cancer progression. J Cell Mol Med (2015) 0.75
Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - hypoxia-induced factors. Contemp Oncol (Pozn) (2012) 0.75
Renal cell carcinoma with intramyocardial metastases. BMC Urol (2014) 0.75
Minute kinetics of proapoptotic proteins: BAX and Smac/DIABLO in living tumor cells revealed by homeostatic confocal microscopy. Cytotechnology (2004) 0.75
Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. Future Oncol (2014) 0.75
Functional Assessment of Synoptic Pathology Reporting for Ovarian Cancer. Pathobiology (2016) 0.75